ALTERITY THERAPEUTICS LTD
ATHE, PRNAD · Pharmaceutical Preparations · EDGAR filings ↗
Grade
B72gen composite 59pct→72
Notable findings
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)
Supply chain
Customers (0)
Suppliers (1)
- Catalent
Named in the 10-K; linked when we track them.
Key metrics
Return on equity
-28.6%
Return on assets
-26.4%
Current ratio
13.0×
Tangible book value
$28M
Cash & investments
$22M
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| Babarczy Julian Michael | Director | — |
| Gozlan Lawrence Bernard | Director | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-08-29 | 2025-06-30 | 0001213900-25-082027 ↗ |
| 20-F | 2024-09-26 | 2024-06-30 | 0001213900-24-082281 ↗ |
| 20-F | 2023-08-31 | 2023-06-30 | 0001213900-23-072629 ↗ |
| 20-F | 2022-08-31 | 2022-06-30 | 0001213900-22-052529 ↗ |
| 20-F | 2021-09-02 | 2021-06-30 | 0001213900-21-046254 ↗ |
| 20-F | 2020-09-15 | 2020-06-30 | 0001213900-20-026557 ↗ |
| 20-F | 2019-08-30 | 2019-06-30 | 0001213900-19-016984 ↗ |
| 20-F | 2018-08-31 | 2018-06-30 | 0001144204-18-047425 ↗ |
| 20-F | 2017-08-31 | 2017-06-30 | 0001178913-17-002596 ↗ |
| 20-F | 2016-10-04 | 2016-06-30 | 0001178913-16-006614 ↗ |
| 20-F | 2015-08-26 | 2015-06-30 | 0001178913-15-002715 ↗ |
| 20-F | 2014-11-03 | 2014-06-30 | 0001178913-14-003317 ↗ |